Targets › HTR3D
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Dec 2026.
Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons. (UniProt, Q70Z44)
Open in Phaseline: the race on HTR3D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Seoul National University Hospital | Ramosetron Serotonin 3 (5-HT3) receptor antagonist | HTR3A, HTR3E, HTR3B, HTR3D, HTR3C | Phase 2 | Fecal Incontinence | Dec 2026 |
Fecal Incontinence (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.